Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Eprosartan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 known ✓ | P30556 | 2/20 | 1.00 |
| ▸ | ABCC3 | O15438 | 1/20 | 1.00 |
| ▸ | ABCC2 | Q92887 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Eprosartan SCHEMBL1815060 | 1.00 | AGTR1 (1.00) | AGTR1ABCC3ABCC2 | |
| Eprosartan SCHEMBL4026 | 1.00 | AGTR1 (1.00) | AGTR1ABCC3ABCC2 | |
| Eprosartan SCHEMBL156290 | 1.00 | AGTR1 (1.00) | AGTR1ABCC3ABCC2 | |
| Eprosartan SCHEMBL7405237 | 0.99 | AGTR1 (0.98) | AGTR1ABCC3ABCC2 | |
| Eprosartan SCHEMBL1119964 | 0.99 | AGTR1 (0.98) | AGTR1ABCC3ABCC2 | |
| Eprosartan SCHEMBL1119965 | 0.99 | AGTR1 (0.98) | AGTR1ABCC3ABCC2 | |
| Eprosartan SCHEMBL7405236 | 0.99 | AGTR1 (0.98) | AGTR1ABCC3ABCC2 | |
| Eprosartan SCHEMBL1897811 | 0.99 | AGTR1 (0.98) | AGTR1ABCC3ABCC2 | |
| Eprosartan SCHEMBL6747994 | 0.99 | AGTR1 (0.98) | AGTR1ABCC3ABCC2 | |
| Eprosartan SCHEMBL6747993 | 0.99 | AGTR1 (0.98) | AGTR1ABCC3ABCC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 22073 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122036573-A | Drug design strategy for releasing hydrogen sulfide based on enzymolysis thiocarbonyl and application of drug design strategy in diclofenac-like drug modification | 中国药科大学 | 2026-05-15 | — | — | CN | claimed |
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| US-12605384-B2 | Uses | INTRA-CELLULAR THERAPIES, INC. (US) | 2026-04-21 | — | — | US | claimed |
| EP-4724049-A1 | MODIFIED RELEASE FILL COMPOSITIONS FOR DOSAGE FORMS AND METHODS OF PREPARATION AND USE THEREOF | Catalent Ontario Limited (CA) | 2026-04-15 | — | — | EP | claimed |
| US-20260083726-A1 | COMPOSITIONS, SYSTEMS, AND METHODS FOR TREATING CANCER USING TUMOR TREATING FIELDS, CHEMOTHERAPEUTIC AGENTS, AND ANTI-FIBROTIC AGENTS | NOVOCURE GMBH (CH) | 2026-03-26 | — | — | US | claimed |
| EP-4215194-B1 | COMBINATION THERAPY OF AT1 R BLOCKER AND CCR2 INHIBITOR FOR THE TREATMENT, AMELIORATION OR PREVENTION OF A KIDNEY DISEASE | DIMERIX BIOSCIENCE PTY LTD (AU) | 2026-03-25 | — | — | EP | claimed |
| EP-4709364-A1 | THERAPEUTIC FORMULATIONS FOR KIDNEY DISEASE COMPRISING REPAGERMANIUM OR PROPAGERMANIUM AND/OR AT1R BLOCKERS | Dimerix Bioscience Pty Ltd (AU) | 2026-03-18 | — | — | EP | claimed |
| EP-4710928-A2 | METHODS OF TREATING IGA NEPHROPATHY WITH ATRASENTAN | Chinook Therapeutics, Inc. (US) | 2026-03-18 | — | — | EP | claimed |
| EP-4711006-A2 | COMBINATION THERAPY OF AT1 R BLOCKER AND CCR2 INHIBITOR FOR THE TREATMENT, AMELIORATION OR PREVENTION OF A KIDNEY DISEASE | Dimerix Bioscience Pty Ltd (AU) | 2026-03-18 | — | — | EP | claimed |
| EP-4694856-A1 | CALENDAR MEDICATION BLISTER PACK, METHOD OF USING THEREOF AND ELECTRONIC SYSTEM OF MANAGEMENT OF INTERACTION WITH CALENDAR MEDICATION BLISTER PACK | Mili Healthcare Trade Fzco (AE) | 2026-02-18 | — | — | EP | claimed |
| WO-1996040255-A2 | METHOD TO TREAT CARDIOFIBROSIS WITH A COMBINATION THERAPY OF AN ANGIOTENSIN II ANTAGONIST AND AN EPOXY-STEROIDAL ALDOSTERONE ANTAGONIST | G.D. SEARLE & CO. (US) | 1996-12-19 | — | — | WO | claimed |
| WO-1996040257-A1 | EPOXY-STEROIDAL ALDOSTERONE ANTAGONIST AND ANGIOTENSIN II ANTAGONIST COMBINATION THERAPY FOR TREATMENT OF CONGESTIVE HEART FAILURE | G.D. SEARLE & CO. (US) | 1996-12-19 | — | — | WO | claimed |
| WO-1996040258-A2 | SPIRONOLACTONE AND ANGIOTENSIN II ANTAGONIST COMBINATION THERAPY FOR TREATMENT OF CONGESTIVE HEART FAILURE | G.D. SEARLE & CO. (US) | 1996-12-19 | — | — | WO | claimed |
| WO-1995029674-A1 | A METHOD OF MODIFYING ANGIOTENSIN RECEPTOR ACTIVITY FOR TREATMENT OF PREMENSTRUAL SYNDROME AND MEDIATION OF PAIN | DEPADOVA ANTHONY S (US) | 1995-11-09 | — | — | WO | claimed |
| US-5464854-A | Method of modifying ovarian hormone-regulated AT1 receptor activity as treatment of incapacitating symptom(s) of P.M.S. | DEPADOVA ANATHONY S (US) | 1995-11-07 | — | — | US | claimed |
| EP-0565634-A1 | ANGIOTENSIN II RECEPTOR BLOCKING COMPOSITIONS | SMITHKLINE BEECHAM CORPORATION (US) | 1993-10-20 | — | — | EP | claimed |
| WO-1993006828-A1 | MEDICAMENT FOR THE TREATMENT OF ANXIETY | SMITHKLINE BEECHAM CORPORATION (US) | 1993-04-15 | — | — | WO | claimed |
| US-5185351-A | Hypotensive agents; for treatment of congestive heart failure, renal failure and glaucoma | SMITHKLINE BEECHAM CORPORATION (US) | 1993-02-09 | — | — | US | claimed |
| WO-1992010097-A1 | ANGIOTENSIN II RECEPTOR BLOCKING COMPOSITIONS | SMITHKLINE BEECHAM CORPORATION (US) | 1992-06-25 | — | — | WO | claimed |
| EP-0403159-A2 | Imidazolyl-alkenoic acids | SMITHKLINE BEECHAM CORPORATION (US) | 1990-12-19 | — | — | EP | claimed |